{"filing":{"accession_number":"0001628280-26-054274","cik":"0001479681","ticker":"NUTX","company_name":"Nutex Health Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"nutx-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1479681/000162828026054274/nutx-20260806.htm"},"events":[{"id":25885,"run_id":23501,"accession_number":"0001628280-26-054274","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Nutex Health's financial results for Q2 and H1 2026. The Item 2.02 disclosure explicitly states \"On August 6, 2026, Nutex Health Inc. announced its financial and operating results for the second quarter ending June 30, 2026\" with a press release furnished as Exhibit 99.1. The exhibit contains detailed financial statements, revenue figures ($427.2M for six months), net income ($112.6M), diluted EPS ($15.87), and operating cash flow ($109.7M), along with management commentary on performance. This is material to investors as it reports significant year-over-year improvements in profitability and cash generation.","company_name":"Nutex Health Inc.","ticker":"NUTX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26819,"accession_number":"0001628280-26-054274","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Nutex Health's financial results for Q2 and H1 2026. The Item 2.02 disclosure explicitly states \"On August 6, 2026, Nutex Health Inc. announced its financial and operating results for the second quarter ending June 30, 2026\" with a press release furnished as Exhibit 99.1. The exhibit contains detailed financial statements, revenue figures ($427.2M for six months), net income ($112.6M), diluted EPS ($15.87), and operating cash flow ($109.7M), along with management commentary on performance. This is material to investors as it reports significant year-over-year improvements in profitability and cash generation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:40:58.466052+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26819,"accession_number":"0001628280-26-054274","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Nutex Health's financial results for Q2 and H1 2026. The Item 2.02 disclosure explicitly states \"On August 6, 2026, Nutex Health Inc. announced its financial and operating results for the second quarter ending June 30, 2026\" with a press release furnished as Exhibit 99.1. The exhibit contains detailed financial statements, revenue figures ($427.2M for six months), net income ($112.6M), diluted EPS ($15.87), and operating cash flow ($109.7M), along with management commentary on performance. This is material to investors as it reports significant year-over-year improvements in profitability and cash generation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:40:58.466052+00:00","company_name":"Nutex Health Inc.","ticker":"NUTX","filing_date":"2026-08-06"}]}